agCapture 3.2 Delivers on the Promise of Real Unification of Data Management Processes
ArisGlobal, a leading provider of solutions to the life sciences industry, has announced the immediate availability of agCapture™ 3.2, the newest release of ArisGlobal’s innovative EDC (Electronic Data Capture) system, fully unified with ePRO (electronic Patient Reported Outcome) RTSM (Randomization and Trial Supply Management), IWRS (Interactive Web Response System) and medical coding, and seamlessly integrated with CTMS (Clinical Trial Management System). agCapture is offered either as an on-premise or cloud solution.
“Trial sponsors are constantly searching for ways to reduce study costs and improve efficiencies while adhering to compliance requirements,” stated Simon Sparkes, executive vice president, ArisGlobal. “agCapture is simply a stand-out EDC system that is not only unified with our advanced ePro, RTSM and IWRS solutions, but is now fully integrated with CTMS using CDISC ODM (Clinical Data Interchange Standards Consortium Operational Data Model) standards as the basis of the integration. There is quite simply no other clinical drug development platform to match the ArisGlobal eClinical solution suite.”
agCapture 3.2 delivers many key features and enhancements that ensure a successful clinical study:
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.